4D Molecular Therapeutics strengthens cash position, eyes Phase 3 success for 4D-150

4D Molecular Therapeutics (4DMT) has announced its full-year 2024 financial results, highlighting key advancements in its late-stage clinical pipeline. With a primary focus on its leading candidate, 4D-150, the company is making significant strides in the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The biotechnology firm has reinforced its [R